CHRONIC LYMPHOCYTIC LEKEMIA

Poster number

Title

Submitting author

City and Country

127

Cladribine as frontline treatment of hairy cell leukemia: a multicenter European experience of more than 30 years on 384 patients

Alessandro Broccoli

Bologna, Italy

128

MOLTO, a multicenter, open label, uncontrolled, phase II clinical trial on venetoclax, atezolizumab, obinutuzumab in Richter Transformation: safety interim analysis

Anna Maria Frustaci

Milan, Italy

129

Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent BTK inhibitor in previously treated Richter transformation: Results from the phase 1/2 BRUIN study

Wojciech Jurczak

Krakow, Poland

130

Preliminary results of the Phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib

Mazyar Shadman

Seattle, WA, USA

131

Updated Efficacy and Safety Results of Orelabrutinib in the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Wei Xu

Nanjing, China

132

Safety and Effectiveness of Venetoclax Monotherapy in Elderly Patients with Relapsed/Refractory CLL Under Real-Life Conditions – Data From the Observational Study VeRVe

Ingo Schwaner

Berlin, Germany

133

Ibrutinib tolerability and outcome in patients with high-risk chronic lymphocytic leukemia

Adalgisa Condoluci

Bellinzona, Switzerland

134

EFFICACY AND DISCONTINUATION RATE OF IBRUTINIB IN TREATMENT NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH TP53 ABNORMALITIES. A REAL-LIFE CAMPUS CLL STUDY

Andrea Visentin

Padova, Italy

135

Ibrutinib followed by Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC-7 Trial from the Spanish Group of CLL (GELLC)

Pau Abrisqueta

Barcelona, Spain

136

First-Line Treatment With Ibrutinib for Patients With Chronic Lymphocytic Leukemia (CLL): 7-Year Results From RESONATE-2

Steven Coutre

Stanford, CA, USA

137

Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 4-year follow-up analysis of the randomized CLL14 study

Othman Al-Sawaf

Cologne, Germany

138

Unfavorable genetics impact MRD response to venetoclax+rituximab retreatment in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): Phase 3 MURANO substudy

John Seymour

Melbourne, Australia

139

A Continuous Individualized Risk Index for refined outcome prediction after targeted therapy for patients with chronic lymphocytic leukemia (CIRI-CLL)

Othman Al-Sawaf

Cologne, Germany

140

A Cross-sectional Study on the Global Differences in Information Experiences and Needs of Patients with Lymphoma and CLL

Lorna Warwick

Mississauga, Canada

141

Impact of disease treatment on the outcome of patients with Chronic Lymphocytic Leukemia (CLL) with COVID-19: a multicenter study on behalf of GELLC

Ana Muntañola

Barcelona, Spain

142

Dissecting the genetics of different anatomical compartments of small lymphocytic lymphoma with a multiregional sequencing apporach.

Riccardo Moia

Novara, Italy

143

Kinase-dead Bruton’s tyrosine kinase (BTK) C481F/Y mutants confer ibrutinib resistance through activation of hematopoietic cell kinase (HCK)

Kamaldeep Dhami

Sunnyvale, CA, USA